Abstract
New pyrazole-based thiazolyl hydrazone derivatives were obtained via the ring closure reaction of 3,5- dimethyl-1H-1-phenylpyrazole-4-carboxaldehyde thiosemicarbazone with 2-bromoacetophenone derivatives. The compounds were investigated for their cytotoxic effects on A549 and NIH3T3 cell lines. Among these compounds, compound 2i bearing a trifluoromethyl substituent can be identified as the most promising anticancer agent against A549 cancer cell lines. Compound 2i exhibited its inhibitory effect on A549 cells with an IC50 value of 0.0316 mM, whereas cisplatin showed its anticancer activity with an IC50 value of 0.01 mM. According to the IC50 values, the inhibitory effect of compound 2i on A549 cells can be considered to be selective when compared with its effect on NIH3T3 cells.
Keywords: Anticancer activity, Hydrazone, Pyrazole, Thiazole.
Letters in Drug Design & Discovery
Title:Synthesis and Biological Evaluation of New Pyrazole-based Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents
Volume: 11 Issue: 7
Author(s): Mehlika Dilek Altıntop, Ahmet Ozdemir, Sinem Ilgın and Ozlem Atli
Affiliation:
Keywords: Anticancer activity, Hydrazone, Pyrazole, Thiazole.
Abstract: New pyrazole-based thiazolyl hydrazone derivatives were obtained via the ring closure reaction of 3,5- dimethyl-1H-1-phenylpyrazole-4-carboxaldehyde thiosemicarbazone with 2-bromoacetophenone derivatives. The compounds were investigated for their cytotoxic effects on A549 and NIH3T3 cell lines. Among these compounds, compound 2i bearing a trifluoromethyl substituent can be identified as the most promising anticancer agent against A549 cancer cell lines. Compound 2i exhibited its inhibitory effect on A549 cells with an IC50 value of 0.0316 mM, whereas cisplatin showed its anticancer activity with an IC50 value of 0.01 mM. According to the IC50 values, the inhibitory effect of compound 2i on A549 cells can be considered to be selective when compared with its effect on NIH3T3 cells.
Export Options
About this article
Cite this article as:
Altıntop Dilek Mehlika, Ozdemir Ahmet, Ilgın Sinem and Atli Ozlem, Synthesis and Biological Evaluation of New Pyrazole-based Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents, Letters in Drug Design & Discovery 2014; 11 (7) . https://dx.doi.org/10.2174/1570180811666140226235350
DOI https://dx.doi.org/10.2174/1570180811666140226235350 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Endoglin (CD105): A Target for Anti-angiogenetic Cancer Therapy
Current Drug Targets SCF E3 Ubiquitin Ligases as Anticancer Targets
Current Cancer Drug Targets Overview on Anticancer Drug Design and Development
Current Medicinal Chemistry Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design Simultaneous Amplification of HER-2 (ERBB2) and Topoisomerase IIα (TOP2A) Genes - Molecular Basis for Combination Chemotherapy in Cancer
Current Cancer Drug Targets Cancer Cachexia: One Step Ahead
Reviews on Recent Clinical Trials Advancing of Cellular Signaling Pathways in Respiratory Diseases Using Nanocarrier Based Drug Delivery Systems
Current Pharmaceutical Design The Role of MicroRNAs in Lung Cancer: Implications for Diagnosis and Therapy
Current Molecular Medicine PARP Inhibitors in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Current Radiopharmaceuticals Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
Current Topics in Medicinal Chemistry Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Sequence and Structural Elements in the Mechanism of Function of Rhodopsin-Like Family of G Protein-Coupled-Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Future Oncotargets: Targeting Overexpressed Conserved Protein Targets in Androgen Independent Prostate Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry International Conference on Personalized Medicine: “Genes and Medicine” 19-20 September 2009, Hong Kong Science Park, Hong Kong SAR
Current Pharmacogenomics and Personalized Medicine Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors
Mini-Reviews in Medicinal Chemistry Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Recent Studies and Biological Aspects of Substantial Indole Derivatives with Anti-cancer Activity
Current Organic Chemistry